Journal
CANCER DISCOVERY
Volume 8, Issue 3, Pages 269-271Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-18-0075
Keywords
-
Categories
Funding
- CANCER-ID - Innovative Medicines Joint Undertaking (IMIJU)
- Servier
- Austrian National Bank (ONB) [16917]
- Austrian Science Fund (FWF) [P28949-B28]
- Bio-TechMed-Graz flagship project EPIAge
- Christian Doppler Research Fund for Liquid Biopsies for Early Detection of Cancer
- Austrian Science Fund (FWF) [P28949] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
In this issue of Cancer Discovery, Miyamoto and colleagues adapted their microfluidic CTC-iChip isolation platform with a digital RNA-PCR readout for eight prostate-specific transcripts and two assays for the androgen receptor mRNA splice variant ARV7 and the TMPRSS2-ERG translocation transcript. In patients with metastatic castrate-resistant prostate cancer at initiating abiraterone therapy in a first-line setting, the resulting RNA-based digital circulating tumor cell signatures identified patients with a shorter overall survival, and in patients with clinically localized disease, the signatures identified those with seminal vesicle invasion and pelvic lymph node involvement. (c) 2018 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available